Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

@article{OBrien2003ImatinibCW,
  title={Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.},
  author={Stephen G. O’Brien and François Guilhot and Richard A. Larson and Insa Gathmann and Michele Baccarani and Francisco Cervantes and Jan J Cornelissen and Thomas J. Fischer and Andreas Hochhaus and Timothy P. Hughes and Klaus Lechner and Johan Lanng Nielsen and Philippe Rousselot and Josy Reiffers and Giuseppe Saglio and John D. Shepherd and Bengt Simonsson and Alois Gratwohl and John M. Goldman and Hagop M. Kantarjian and Kerry E. Taylor and Gregor E. G. Verhoef and Ann E Bolton and Renaud Capdeville and Brian J. Druker},
  journal={The New England journal of medicine},
  year={2003},
  volume={348 11},
  pages={
          994-1004
        }
}
BACKGROUND Imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, produces high response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have had no response to interferon alfa. We compared the efficacy of imatinib with that of interferon alfa combined with low-dose cytarabine in newly diagnosed chronic-phase CML. METHODS We randomly assigned 1106 patients to receive imatinib (553 patients) or interferon alfa plus low-dose cytarabine (553 patients). Crossover… 

Figures and Tables from this paper

Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase

First-line imatinib-treated patients had profound reductions in BCR-ABL/BCR%, which significantly exceeded those of IFN+AraC- treated patients and early measurements were predictive of subsequent response.

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.

The proportion of patients with CML who had a reduction in BCR-ABL transcript levels of at least 3 log by 12 months of therapy was far greater with imatinib treatment than with treatment with interferon plus cytarabine.

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

After 5 years of follow-up, continuous treatment of chronic-phase CML with imatinib as initial therapy was found to induce durable responses in a high proportion of patients.

Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia.

Imatinib should now be considered the standard therapy for newly diagnosed patients with CML, reflecting efficient rescue of IFN/LDAC failures with imatinib.

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.

High-dose imatinib induced higher rates of complete cytogenetic response and of molecular response in patients with newly diagnosed chronic phase CML, and was well tolerated but resulted in more frequent myelosuppression.

Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group

The results indicate the benefit of early intervention during imatinib therapy and suggest there is room for improvement in the front line results in chronic-phase chronic myeloid leukemia.

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.

Nilotinib has a relatively favorable safety profile and is active in imatinib-resistant CML, and common adverse events were myelosuppression, transient indirect hyperbilirubinemia, and rashes.

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.

Bosutinib may offer a new treatment option for patients with chronic-phase CML after treatment with multiple TKIs and had an acceptable safety profile; treatment-emergent adverse events were primarily manageable grade 1/2 gastrointestinal events and rash.

Long‐Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

Almost 11 years of follow-up showed that the efficacy of Imatinib persisted over time and that long‐term administration of imatinib was not associated with unacceptable cumulative or late toxic effects.

The response to imatinib and interferon-α is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase

Data suggest that the response to the combination treatment of IFN-α with imatinib is more rapid, and it is not yet known how much a rapid reduction will influence the longer-term overall and progression free survival, and the cure rate.
...

References

SHOWING 1-10 OF 36 REFERENCES

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.

Imatinib induced high rates of cytogenetic and hematologic responses in patients with chronic-phase CML in whom previous interferon therapy had failed, and CML had not progressed to the accelerated or blast phases after a median follow-up of 18 months.

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.

Orally administered imatinib is an effective and well-tolerated treatment for patients with CML in accelerated phase, and a daily dose of 600 mg is more effective than 400 mg, with similar toxicity.

Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group.

The combination of interferon and cytarabine, as compared withinterferon alone, increases the rate of major cytogenetic response and prolongs survival in patients with the chronic phase of chronic myelogenous leukemia.

Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group.

The problems of conventional prognostic scores that the authors observed in IFN-treated patients support the idea that IFN changes the natural course of CML, and whether and to what extent IFN is superior to HU appears to depend on the degree of WBC suppression by HU-therapy and on the risk profile of the patients.

A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia.

The results of this study confirm the results of a similar French study only for the response rate, not for survival, suggesting that the relationship between cytogenetic response and survival may be extremely variable and that a meta-analysis is required to settle the issue of the role of LDAC in the treatment of CML.

A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase.

It is demonstrated that IFN-alpha treatment produces a significantly superior cytogenetic response and survival rate as compared with the busulfan treatment, and unexpectedly, thatBusulfan can also eliminate Philadelphia chromosome positive clone in a few patients who showed prolonged survival rate and duration of chronic phase.

Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon-alpha 2b for chronic myeloid leukemia. The Benelux CML Study Group.

Although the hematologic and cytogenetic responses in the IFN group were higher than in the control group, the duration of chronic phase from randomization was not statistically different and no advantage for survival calculated from diagnosis was seen.

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

STI571 is well tolerated and has significant antileukemic activity in patients with CML in whom treatment with interferon alfa had failed and demonstrates the potential for the development of anticancer drugs based on the specific molecular abnormality present in a human cancer.

Chronic myeloid leukemia: current treatment options.

Allogeneic stem cell transplantation soon after diagnosis should continue to be offered as an option for selected patients, and two contrasting options are considered for managing the patient with newly diagnosed disease.